Lori J. Wirth, MD

Articles

RET and NTRK Inhibitors for Differentiated Thyroid Cancer

January 28th 2022

The rationale for targeting actionable mutations in differentiated thyroid cancer with RET and NTRK inhibitors.

Systemic Therapy Algorithms in DTC

January 28th 2022

Considerations regarding approaches to sequencing therapies for differentiated thyroid cancer.

Targeted Treatments for Differentiated Thyroid Cancer

January 21st 2022

An overview of the types of targeted drug classes available to treat differentiated thyroid cancer at various clinical stages.

When to Initiate Therapy for Differentiated Thyroid Cancer

January 21st 2022

Maria E. Cabanillas, MD, describes what triggers her to initiate therapy for differentiated thyroid cancer and variables that impact treatment choice.

Dr. Wirth on the Utility of Tipifarnib in Head and Neck Cancer

January 4th 2022

Lori J. Wirth, MD, discusses the utility of tipifarnib in patients with head and neck cancer whose tumors harbor HRAS mutations.

Dr. Wirth on the LIBRETTO-531 Trial With Selpercatinib in RET+ Medullary Thyroid Cancer

November 5th 2021

Lori J. Wirth, MD, discusses the phase 3 LIBRETTO-531 trial of selpercatinib in patients with RET-mutant medullary thyroid cancer. 

Dr. Wirth on Takeaways From the SELECT Trial in Thyroid Cancer

August 31st 2018

Lori J. Wirth, MD, associate professor of medicine, Harvard Medical School, medical director, Center for Head and Neck Cancers, Massachusetts General Hospital, discusses takeaways from the SELECT trial in patients with thyroid cancer.

Dr. Wirth on the Use of Lenvatinib in Hypertensive Patients With Thyroid Cancer

June 18th 2018

Lori J. Wirth, MD, associate professor, Medicine, Harvard Medical School, medical director, Center for Head and Neck Cancers, Massachusetts General Hospital, discusses the use of lenvatinib in hypertensive patients with thyroid cancer.

Dr. Wirth Discusses the Safety Profile of Lenvatinib as Seen in the SELECT Trial

July 15th 2014

Lori J. Wirth, MD, medical director, Center for Head and Neck Cancers, Massachusetts General Hospital, assistant professor, Harvard Medical School, discusses the safety profile of lenvatinib as seen in the phase III SELECT trial, which analyzed lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer.